Archive | Press Releases

China TMK Battery Systems Inc. to Explore Strategic Options

China TMK Battery Systems Inc. to Explore Strategic Options

China TMK Battery Systems Inc. (OTC Bulletin Board: DFEL) (“TMK” or “the Company”) (formerly, Deerfield Resources, Ltd.), a Chinese manufacturer and distributor of customized rechargeable battery solutions to global consumer product companies, today announced that on December 30, 2011, it filed a Certification and Notice of Suspension of Duty to File Reports with the Securities and Exchange Commission (the “SEC”) in order to reduce substantial legal and accounting expenses. The Company was eligible to deregister its common shares because it had fewer than 300 holders of record of its common shares at the beginning of its fiscal year.

The Board of Directors is in the process of evaluating strategic alternatives for the Company including a sale, merger, privatization, or other business combination, however, the Company has not set a timetable for completion of this evaluation process and there can be no assurances that this review will result in any action. The Company does not expect to make any further comments unless the Board of Directors has approved a specific course of action or otherwise deems disclosure appropriate.

“We believe our company has a bright future ahead,” explained Mr. Henian Wu, Chairman and President of the Company. “Since we became a public company in February 2010, our revenues have increased from $48.6 million in 2009 to an estimated $84 million in 2011, significantly faster than the industry. Despite this strong performance and ongoing efforts to strengthen our competitive position, our stock continues to trade at a depressed valuation. We expect that the Company will have attractive options to consider. In the meantime, our Management team will continue to focus on executing our business plan and serving our customers.”

The Company’s Form 15 filing on December 30, 2011 immediately suspended the Company’s obligation to file certain reports with the SEC, including Forms 10-K, 10-Q and 8-K, however, the Company’s common stock will continue to be quoted on the OTCQB and eligible shareholders may continue to avail themselves of legend removal under Rule 144 until the deregistration becomes effective. The Company expects that the deregistration of its common stock will become effective on or before March 31, 2012. Following deregistration, the Company’s common shares will only be quoted on the OTC Pink Sheets and its shareholders may no longer avail themselves of Rule 144.

About China TMK Battery Systems Inc.

Based in Shenzhen, PRC and founded in 1999, TMK manufactures and distributes high rate discharge Nickel Metal Hydride (“Ni-MH”) multi-cell batteries in its manufacturing facility located in Shenzhen, China. TMK maintains a diverse roster of large, consumer-focused clients with major production facilities in China. The Company works with its clients throughout the product design cycle to develop and integrate reliable and long-lasting rechargeable power solutions for widely used consumer products, which include home appliances, cordless power tools, medical devices, multiple personal communication devices and electric bicycles segments. The Company is also focused on becoming a supplier of back-up power solutions to the telecommunications industry and for traffic lighting applications. Corporate Information can be found at www.tmk-battery.com and investor information can be found at http://ir.stockpr.com/tmk-battery/

Posted in Press ReleasesComments (0)

VisionChina Media Announces Results of 2011 Annual General Meeting of Shareholders

VisionChina Media Announces Results of 2011 Annual General Meeting of Shareholders

VisionChina Media Inc. (“VisionChina Media” or the “Company”) (Nasdaq: VISN), one of China’s largest out-of-home digital television advertising networks on mass transportation systems, today announced it has obtained shareholder approval for all matters submitted for approval at the Company’s 2011 annual general meeting, held in Hong Kong on December 28, 2011.

The following resolution proposed by the Company was approved by VisionChina Media’s shareholders:

Ratification of the appointment of Deloitte Touche Tohmatsu CPA Ltd. as the Company’s independent auditors for the year ending December 31, 2011.

Materials related to the annual general meeting of shareholders, including the proxy statement, are available on the Company’s website at http://www.visionchina.cn .

About VisionChina Media Inc.

VisionChina Media Inc. (Nasdaq: VISN) operates an out-of-home advertising network on mass transportation systems, including buses and subways. As of September 30, 2011, VisionChina Media’s advertising network included 136,777 digital television displays on mass transportation systems in 20 of China’s economically prosperous cities, including Beijing, Shanghai, Guangzhou and Shenzhen. VisionChina Media has the ability to deliver real-time, location-specific broadcasting, including news, stock quotes, weather and traffic reports, and other entertainment programming. For more information, please visit http://www.visionchina.cn .

For investor and media inquiries, please contact:

In China:

Mr. Colin Wang

Investor Relations Director

VisionChina Media Inc.

Tel: +86-135-1001-0107

Email: colin.wang@visionchina.cn

Mrs. Helen Plummer

Investor Relations Adviser

VisionChina Media Inc.

Tel: +86-139-1167-2124

Email: helen.plummer@visionchina.cn

In the United States:

Ms. Jessica Barist Cohen

Ogilvy Financial, New York

Tel: +1-646-460-9989

E-mail: jessica.cohen@ogilvy.com

SOURCE VisionChina Media Inc.

Posted in Press ReleasesComments (0)

China Direct Industries Provides Update for its Magnesium Segment Sales

China Direct Industries Provides Update for its Magnesium Segment Sales

China Direct Industries, Inc. (“China Direct Industries”) (NASDAQ:CDII), a U.S. based company that produces, sources, and distributes industrial commodities in China and the Americas and provides cross border corporate advisory services announced today that its magnesium segment operations received five new purchase contracts from existing customers, including major Fortune 500 companies, valued at approximately $11.0 million in December of 2011 for delivery over the next six months.

Commenting on the contracts, Dr. James Wang , Chairman and CEO of China Direct Industries, Inc., stated “We are pleased to see an increase in orders and quoting activity as we head into calendar 2012.  We believe that our magnesium segment will strengthen further throughout the coming year as economic conditions which weakened short term demand begin to abate.”

About China Direct Industries, Inc.

China Direct Industries, Inc. (NASDAQ: CDII), is a U.S. based company that produces, sources, and distributes industrial commodities in China and the Americas and provides business and financial consulting services.  Headquartered in Deerfield Beach, Florida with corporate offices in Shanghai, China Direct Industries’ unique infrastructure provides a platform to expand business opportunities globally while effectively and efficiently accessing the U.S. capital markets. For more information about China Direct Industries, please visit http://www.cdii.net.

DISCLOSURE NOTICE:

In connection with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, China Direct Industries, Inc., is hereby providing cautionary statements identifying important factors that could cause our actual results to differ materially from those projected in forward-looking statements (as defined in such act). Any statements that are not historical facts and that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, indicated through the use of words or phrases such as “will likely result,” “are expected to,” “will continue,” “is anticipated,” “estimated,” “intends,” “plans,” “believes” and “projects”) may be forward-looking and may involve estimates and uncertainties which could cause actual results to differ materially from those expressed in the forward-looking statements. These statements include, but are not limited to, our expectations concerning demand for our magnesium products and economic conditions.

We caution that the factors described herein could cause actual results to differ materially from those expressed in any forward-looking statements we make and that investors should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. New factors emerge from time to time, and it is not possible for us to predict all of such factors. Further, we cannot assess the impact of each such factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. This press release is qualified in its entirety by the cautionary statements and risk factor disclosure contained in our Securities and Exchange Commission filings, including our Report on Form 10-K for the fiscal year ended September 30, 2011 .

Posted in Press ReleasesComments (0)

China Botanic Exhibits All-Natural Anti-depressant Products

China Botanic Exhibits All-Natural Anti-depressant Products

China Botanic Pharmaceutical Inc. (NYSE AMEX: CBP) (“China Botanic” or the “Company”), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and Traditional Chinese Medicines (“TCM”) in China, today announced that the Company successfully showcased its all-natural products at the 66th PHARMCHINA fair (“the Fair”) recently held in Zhengzhou, China.

China Botanic’s all-natural and plant based remedies attracted significant attention and interest from manufacturers, distributors, and other attendees at the Fair. The Company was focused on increasing knowledge and awareness of its all natural products which are beneficial in treatment and prevention of depression. Over 20 distributors expressed strong interest in the Company’s anti-depressant products and are seeking to engage in further discussion on potential partnerships. Management estimates an approximate revenue contribution of RMB5 million (or approximately $0.8 million) in fiscal year 2012 from the business generated at the fair compared to the contribution of $0.6million from last year’s fair.

“PHARMCHINA is China’s largest pharmaceutical fair which attracts attendees from all over the country, providing an ideal platform to promote our products and brand,” said Mr. Shaoming Li, Chairman and Chief Executive Officer of China Botanic. “Our focus on the anti-depressant segment reflects the growing customer demand for effective anti-depressant remedies. An estimated 30 million people in China suffer from depression, and yet China has only in recent years listed depression as a disease. We are pleased with the increased awareness we created and the response we received at the fair this year. We will continue to participate in similar events to build disease awareness and long-term brand recognition of our products. At the same time, we continue to grow our business organically and enhance our overall operational efficiency.”

ABOUT PHARMCHINA

PHARMCHINA is the largest exhibition in China’s pharmaceutical industry. With a history of over 30 years, the PHARMCHINA fair covers an area of approximately 70,000 square meters and attracts over 2,800 exhibitors and 120,000 visitors. Twice a year, exhibitors and visitors attend PHARMCHINA for new business opportunities in the rapidly developing China’s pharmaceutical market, including chemical-based drugs, TCM, bio-pharmaceuticals, OTC medicine, health care products, cosmetics, and healthcare-related technologies and other services. For more information, please visit http://en.pharmchina.com.cn/.

ABOUT CHINA BOTANIC PHARMACEUTICAL INC.

China Botanic Pharmaceutical Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines (“TCM”), in the People’s Republic of China. All of the Company’s products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. For more information, please visit www.renhuang.com.

Posted in Press ReleasesComments (0)

Search Articles

Archives